​

Medpace (MEDP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Medpace Revenue Highlights

Latest Revenue (Y)

$2.11B

Latest Revenue (Q)

$533.32M

Main Segment (Y)

Oncology

Medpace Revenue by Period

Medpace Revenue by Year

DateRevenueChange
2024-12-31$2.11B11.84%
2023-12-31$1.89B29.17%
2022-12-31$1.46B27.80%
2021-12-31$1.14B23.38%
2020-12-31$925.92M7.54%
2019-12-31$860.97M22.19%
2018-12-31$704.59M61.55%
2017-12-31$436.15M3.46%
2016-12-31$421.58M17.41%
2015-12-31$359.06M23.80%
2014-12-31$290.04M6.28%
2013-12-31$272.89M-

Medpace generated $2.11B in revenue during NA 2024, up 11.84% compared to the previous quarter, and up 244.96% compared to the same period a year ago.

Medpace Revenue by Quarter

DateRevenueChange
2024-09-30$533.32M0.99%
2024-06-30$528.10M3.34%
2024-03-31$511.04M2.54%
2023-12-31$498.40M1.20%
2023-09-30$492.50M6.86%
2023-06-30$460.87M6.17%
2023-03-31$434.07M10.14%
2022-12-31$394.10M2.70%
2022-09-30$383.74M9.26%
2022-06-30$351.21M6.12%
2022-03-31$330.95M7.26%
2021-12-31$308.55M4.39%
2021-09-30$295.57M6.21%
2021-06-30$278.29M7.05%
2021-03-31$259.96M0.11%
2020-12-31$259.68M12.72%
2020-09-30$230.37M12.38%
2020-06-30$205.00M-11.21%
2020-03-31$230.88M0.43%
2019-12-31$229.89M6.31%
2019-09-30$216.24M1.00%
2019-06-30$214.10M6.66%
2019-03-31$200.74M4.49%
2018-12-31$192.12M7.18%
2018-09-30$179.25M5.35%
2018-06-30$170.14M4.33%
2018-03-31$163.08M44.72%
2017-12-31$112.68M1.84%
2017-09-30$110.64M4.17%
2017-06-30$106.22M-0.37%
2017-03-31$106.61M-1.51%
2016-12-31$108.24M0.41%
2016-09-30$107.80M1.74%
2016-06-30$105.95M6.39%
2016-03-31$99.59M3.69%
2015-12-31$96.04M4.24%
2015-09-30$92.13M4.87%
2015-06-30$87.85M5.81%
2015-03-31$83.03M6.55%
2014-03-31$77.93M-

Medpace generated $533.32M in revenue during Q3 2024, up 0.99% compared to the previous quarter, and up 115.72% compared to the same period a year ago.

Medpace Revenue Breakdown

Medpace Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 22Dec 21Dec 20Dec 19
Antiviral And Anti Infective$156.46M$118.03M$110.98M$86.39M-
Cardiology$230.45M$174.63M$119.69M$91.26M-
Central Nervous System$181.98M$157.94M$121.55M$65.39M-
Metabolic$457.54M$244.68M$159.90M$138.65M-
Oncology$651.24M$467.80M$362.85M$256.77M-
Other$431.38M$296.91M$267.42M$222.51M-
Revenue Net-$1.46B$34.50M$15.90M$18.90M
Direct Revenue-----
Reimbursed Out Of Pocket Revenue-----

Medpace's latest annual revenue breakdown by segment (product or service), as of Dec 24: Oncology (30.88%), Metabolic (21.69%), Other (20.45%), Cardiology (10.93%), Central Nervous System (8.63%), and Antiviral And Anti Infective (7.42%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Mar 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19
Cardiology$58.30M$55.81M$60.70M$55.64M$44.36M$51.13M$46.62M$45.41M$49.80M$42.03M$37.40M$33.15M$34.74M$28.04M$23.76M$27.59M$21.75M$25.90M$22.47M-
Central Nervous System$49.22M$42.10M$46.52M$44.14M$43.99M$37.73M$38.70M$37.13M$43.42M$38.91M$38.49M$35.33M$32.85M$28.55M$24.81M$21.75M$19.22M$23.98M$17.05M-
Metabolic$122.87M$124.73M$106.30M$103.64M$103.12M$87.86M$86.84M$77.49M$63.48M$55.60M$48.12M$47.13M$42.13M$38.14M$32.49M$29.62M$30.21M$36.08M$36.36M-
Oncology$168.17M$164.92M$162.95M$155.20M$149.33M$147.09M$141.95M$124.21M$122.83M$115.54M$105.21M$95.74M$94.72M$93.25M$79.14M$68.63M$65.63M$69.21M$70.61M-
Other$103.18M$107.37M$112.43M$108.40M$106.16M$101.06M$87.10M$80.17M$72.77M$73.56M$70.42M$70.27M$64.09M$64.12M$68.94M$55.54M$45.20M$50.57M$63.84M-
Antiviral And Anti Infective$34.84M$38.38M$39.20M$44.03M$45.55M$36.01M$32.87M$29.69M$31.45M$25.58M$31.32M$26.93M$27.03M$26.19M$30.82M$27.24M$22.99M$25.15M$19.56M-
Revenue Net----$492.50M$460.87M$434.07M$394.10M$383.74M$17.20M$13.30K$10.60M$8.70M$9.90M$5.30M$4.30M$3.40M$2.70M$5.50M$5.20M

Medpace's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Oncology (31.34%), Metabolic (22.90%), Other (19.23%), Cardiology (10.87%), Central Nervous System (9.17%), and Antiviral And Anti Infective (6.49%).

Medpace Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
IQVIQVIA$15.40B$3.90B
LHLaboratory Corporation of America$12.16B$3.28B
ICLRICON Public$8.12B$2.09B
CRLCharles River Laboratories$4.05B$1.03B
IDXXIDEXX Laboratories$3.90B$975.54M
MTDMettler-Toledo$3.87B$954.53M
WATWaters$2.96B$740.30M
RVTYRevvity$2.76B$641.72M
MEDPMedpace$2.11B$533.32M
QGENQiagen$1.97B$458.80M
NEOGNeogen$924.22M$220.98M
TWSTTwist Bioscience$312.97M-

MEDP Revenue FAQ

What is Medpace’s yearly revenue?

Medpace's yearly revenue for 2024 was $2.11B, representing an increase of 11.84% compared to 2023. The company's yearly revenue for 2023 was $1.89B, representing an increase of 29.17% compared to 2022. MEDP's yearly revenue for 2022 was $1.46B, representing an increase of 27.80% compared to 2021.

What is Medpace’s quarterly revenue?

Medpace's quarterly revenue for Q3 2024 was $533.32M, a 0.99% increase from the previous quarter (Q2 2024), and a 8.29% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $528.1M, a 3.34% increase from the previous quarter (Q1 2024), and a 14.59% increase year-over-year (Q2 2023). MEDP's quarterly revenue for Q1 2024 was $511.04M, a 2.54% increase from the previous quarter (Q4 2023), and a 17.73% increase year-over-year (Q1 2023).

What is Medpace’s revenue growth rate?

Medpace's revenue growth rate for the last 3 years (2022-2024) was 44.46%, and for the last 5 years (2020-2024) was 127.78%.

What are Medpace’s revenue streams?

Medpace's revenue streams in c 24 are Antiviral And Anti Infective, Cardiology, Central Nervous System, Metabolic, Oncology, and Other. Antiviral And Anti Infective generated $156.46M in revenue, accounting 7.42% of the company's total revenue, up 32.56% year-over-year. Cardiology generated $230.45M in revenue, accounting 10.93% of the company's total revenue, up 31.96% year-over-year. Central Nervous System generated $181.98M in revenue, accounting 8.63% of the company's total revenue, up 15.22% year-over-year. Metabolic generated $457.54M in revenue, accounting 21.69% of the company's total revenue, up 86.99% year-over-year. Oncology generated $651.24M in revenue, accounting 30.88% of the company's total revenue, up 39.21% year-over-year. Other generated $431.38M in revenue, accounting 20.45% of the company's total revenue, up 45.29% year-over-year.

What is Medpace’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Medpace was Oncology. This segment made a revenue of $651.24M, representing 30.88% of the company's total revenue.